the approval granted by a dra is limited in its scope to the national territory an inventor who is granted a patent for a new and inventive drug may still be denied regulatory approval if clinical tests show potential negative effects of this drug on the human body the originator of a drug thus has to file two separate applications one with the dra for the regulatory approval and another at the patent office for the respective product andor process patents